Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc. 
2. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for the quote from the Clive Maund article published on December 20, 2024

1. For the quoted article (published on December 20, 2024), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989.  The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be  only be construed as a recommendation or solicitation to buy and sell securities.

Rocket Doctor, a virtual healthcare marketplace under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), has been approved as an in-network provider for New York Medicaid, expanding telehealth access to the state's 6.9 million Medicaid beneficiaries. This development is expected to improve healthcare accessibility across New York by providing urgent, primary, and specialty care through Rocket Doctor's virtual healthcare platform. The approval marks a significant milestone in digital healthcare services, particularly in underserved communities where access to traditional medical facilities remains limited. 

The company's platform allows Medicaid recipients to consult board-certified physicians remotely, reducing reliance on emergency room visits and alleviating strain on in-person healthcare facilities. The approval comes as Rocket Doctor continues to advance its virtual healthcare offerings, which are designed to provide timely specialist referrals and mitigate systemic barriers to care. 

Dr. William Cherniak, CEO and founder of Rocket Doctor, highlighted the significance of this initiative, stating in the news release, "By bringing our virtual and hybrid care models to one of the largest Medicaid populations in the country, we are breaking down barriers and ensuring that patients, regardless of their location or financial status, can access the healthcare they need, when they need it."

Rocket Doctor's expansion aligns with broader efforts to integrate virtual healthcare services into public healthcare systems, particularly as States explore digital solutions to reduce medical costs and improve health outcomes. This initiative is part of a larger movement toward value-based care, where technology-driven healthcare solutions aim to increase efficiency and patient satisfaction while reducing unnecessary medical expenditures. 

As the company told Streetwise, "This is a subset of a larger grant supporting a new Healthy Aging initiative, which is underpinned by a large private health foundation (we are unable to use their name in a PR at this time). However, you might want to take a look at CVS Health Foundation grants $4 million as part of its new healthy aging initiative | Nasdaq which was recently announced."

The Digital Health Revolution: AI, Telehealth, and Personalized Care Reshape the Industry

The digital health coaching market has experienced significant growth, driven by advancements in technology, the increasing prevalence of chronic diseases, and the push for patient-centric healthcare solutions. According to Grand View Research, the market was valued at US$10.99 billion in 2024 and was projected to grow at a compound annual growth rate (CAGR) of 12.51% through 2030. Key factors supporting this expansion included the growing penetration of smartphones and mobile platforms, strategic industry partnerships, and government initiatives aimed at improving healthcare accessibility. The report cited statistics from the GSM Association, which indicated that 5.4 billion people subscribed to mobile services globally in 2022, a figure expected to rise to 6.3 billion by 2030.

AI's role in healthcare has extended beyond clinical settings, with applications in diagnostics, workflow automation, and patient engagement. On February 17, Appinventiv reported that AI-driven healthcare solutions were projected to reach a market value of US$188 billion by 2030, growing at a 37% CAGR. The report highlighted AI's ability to enhance patient care through predictive analytics, robotic-assisted surgeries, and fraud detection in insurance claims. It also pointed to the increasing demand for AI-powered virtual assistants and telemedicine solutions, which were transforming traditional patient interactions.

On February 18, the University of Michigan detailed its involvement in an AI-powered mobile clinic initiative aimed at improving healthcare access in rural areas. The project, funded by the Advanced Research Projects Agency for Health (ARPA-H), was developing AI guidance systems to assist medical generalists in performing specialist-level procedures. The initiative aimed to reduce reliance on permanent medical facilities and improve cost efficiency by equipping mobile clinics with advanced diagnostic tools and AI-driven support systems.

Technology has played a crucial role in enhancing digital health coaching, with telehealth, wearable devices, and artificial intelligence (AI) enabling personalized healthcare solutions. On February 21, Forbes reported that digital health ecosystems were reshaping patient care by integrating telehealth, remote monitoring, and digital platforms to improve efficiency, accessibility, and cost-effectiveness. The article highlighted that telehealth had transitioned from a pandemic necessity to a core component of modern healthcare delivery, particularly benefiting rural communities and patients with mobility challenges. It also noted that the increasing adoption of electronic health records (EHRs) and advanced data-sharing platforms was expected to save the U.S. healthcare system billions annually by reducing redundancies and administrative burdens.

Medicaid Approval and EngageWell Partnership Position Rocket Doctor for Expansion

Rocket Doctor's approval as an in-network provider for New York Medicaid is expected to serve as a key catalyst for the company's growth, as per the Treatment.AI investor information. The integration with the state's Medicaid system enables a broad patient base to access Rocket Doctor's platform, potentially driving increased utilization and revenue. While the company has not disclosed a prescribed value for its Medicaid service share, it operates on a per-visit reimbursement model, indicating potential for scalability based on demand.

In addition to Medicaid approval, Rocket Doctor has expanded its partnership with EngageWell, a network dedicated to serving low-income and underserved populations in New York. This collaboration is supported by a US$1 million grant under a broader Healthy Aging initiative. EngageWell's Care Your Way program incorporates telehealth, remote patient monitoring, and social determinants of health to enhance care coordination. Christopher Joseph, executive director of EngageWell, emphasized the importance of digital healthcare solutions, stating, "Through our partnership with Rocket Doctor and support from our provider network, we're using telehealth and remote patient monitoring to advance health equity and connect people to the care they need."

The approval and partnership with EngageWell provide Rocket Doctor with a strategic foothold in New York's Medicaid market, strengthening its position as a leader in virtual healthcare. With its services now accessible to Medicaid beneficiaries, the company is well-positioned to leverage this momentum for further expansion into additional states and healthcare systems.

Third Party Analysis of Treamtent.AI

*On December 20, Technical Analyst Clive Maund noted that Treatment.com AI had established itself as a key player in the AI-driven healthcare transformation. He emphasized that the company's proprietary Global Library of Medicine (GLM) was a central component of its AI-powered platform, which had broad applications across clinical decision support, medical education, and patient triage. Maund identified the company's AI-based tools as valuable assets in improving healthcare efficiency, reducing administrative burdens for professionals, and expanding access to digital health solutions.

According to Maund's analysis, the company's stock had formed a strong technical base, with increasing volume indicating a potential breakout. He highlighted that the stock had undergone a corrective phase following a mid-2024 peak but maintained that the long-term technical indicators remained bullish. "This is considered to be a great point to buy or add to positions in Treatment.com AI," he wrote, pointing to the completion of a head-and-shoulders bottom pattern and strong volume indicators supporting a renewed uptrend.

Ownership and Share Structure

According to Sedi.ca, insiders own approximately 7.7% of Treatment.com AI. Retail investors own the remaining 92.3%.   

The company has 51.25 million outstanding common shares and has 50.6 million free float traded shares.  

As of February 26, the market cap is approximately CA$27.2 million.

Over the past 52 weeks, the company traded between CA$0.355 - 1.11 per share.